Breast cancer is the most common cancer among women worldwide. Due to its complexity in
nature, effective breast cancer treatment can encounter many challenges. Traditional …

The acquisition of ligand‐independent ESR1 mutations during aromatase inhibitor therapy
in metastatic estrogen receptor (ER)‐positive breast cancer is a common mechanism of …

Abstract Models that recapitulate the complexity of human tumors are urgently needed to
develop more effective cancer therapies. We report a bank of human patient-derived …

Importance Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC)
promote ligand-independent receptor activation and resistance to estrogen-deprivation …

Precision oncology is predicated upon the ability to detect specific actionable genomic
alterations and to monitor their adaptive evolution during treatment to counter resistance …

Rational development of targeted therapies has revolutionized metastatic breast cancer
outcomes, although resistance to treatment remains a major challenge. Advances in …

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy
in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations …

Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for
activation. Mutations that constitutively activate ERα without the need for hormone binding …

The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for
neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes …

The clinical management of cancer has evolved in recent years towards more personalized
strategies that require a comprehensive knowledge of the complex molecular features …